FDA Awards Orphan Drug Designation to Remedy for Cirara

The FDA has granted orphan drug designation to Remedy Pharmaceuticals’ Cirara, which is designed to treat acute spinal cord injury and acute subarachnoid hemorrhage.

The designation program provides a unique edge to candidates, including federal grants, eligibility for a seven-year exclusivity period against competitors and tax credits.